Transplant of Hepatocytes, Undifferentiated Mesenchymal Stem Cells, and In Vitro Hepatocyte-Differentiated Mesenchymal Stem Cells in a Chronic Liver Failure Experimental Model: A Comparative Study
- PMID: 28585911
- DOI: 10.6002/ect.2016.0226
Transplant of Hepatocytes, Undifferentiated Mesenchymal Stem Cells, and In Vitro Hepatocyte-Differentiated Mesenchymal Stem Cells in a Chronic Liver Failure Experimental Model: A Comparative Study
Abstract
Objectives: Liver transplant is the cornerstone line of treatment for chronic liver diseases; however, the long list of complications and obstacles stand against this operation. Searching for new modalities for treatment of chronic liver illness is a must. In the present research, we aimed to compare the effects of transplant of undifferentiated human mesenchymal stem cells, in vitro differentiated mesenchymal stem cells, and adult hepatocytes in an experimental model of chronic liver failure.
Materials and methods: Undifferentiated human cord blood mesenchymal stem cells were isolated, pro-pagated, and characterized by morphology, gene expression analysis, and flow cytometry of surface markers and in vitro differentiated into hepatocyte-like cells. Rat hepatocytes were isolated by double perfusion technique. An animal model of chronic liver failure was developed, and undifferentiated human cord blood mesenchymal stem cells, in vitro hepato-genically differentiated mesenchymal stem cells, or freshly isolated rat hepatocytes were transplanted into a CCL4 cirrhotic experimental model. Animals were killed 3 months after transplant, and liver functions and histopathology were assessed.
Results: Compared with the cirrhotic control group, the 3 cell-treated groups showed improved alanine aminotransferase, aspartate aminotransferase, albumin, and bilirubin levels, with best results shown in the hepatocyte-treated group. Histopathologic examination of the treated groups showed improved fibrosis, with best results obtained in the undifferentiated mesenchymal stem cell-treated group.
Conclusions: Both adult hepatocytes and cord blood mesenchymal stem cells proved to be promising candidates for cell-based therapy in liver regeneration on an experimental level. Improved liver function was evident in the hepatocyte-treated group, and fibrosis control was more evident in the undifferentiated mesenchymal stem cell-treated group.
Similar articles
-
Potentials of Differentiated Human Cord Blood-Derived Unrestricted Somatic Stem Cells in Treatment of Liver Cirrhosis.Exp Clin Transplant. 2019 Apr;17(2):251-258. doi: 10.6002/ect.2017.0249. Epub 2018 Oct 19. Exp Clin Transplant. 2019. PMID: 30346265
-
Transplanted endothelial progenitor cells ameliorate carbon tetrachloride-induced liver cirrhosis in rats.Liver Transpl. 2009 Sep;15(9):1092-100. doi: 10.1002/lt.21845. Liver Transpl. 2009. PMID: 19718641
-
Useful properties of undifferentiated mesenchymal stromal cells and adipose tissue as the source in liver-regenerative therapy studied in an animal model of severe acute fulminant hepatitis.Cytotherapy. 2015 Aug;17(8):1052-65. doi: 10.1016/j.jcyt.2015.04.010. Cytotherapy. 2015. PMID: 26139545
-
[Application of mesenchymal stem cells to liver regenerative medicine].Yakugaku Zasshi. 2008 Jan;128(1):3-9. doi: 10.1248/yakushi.128.3. Yakugaku Zasshi. 2008. PMID: 18176050 Review. Japanese.
-
Hepatocyte differentiation of mesenchymal stem cells.Hepatobiliary Pancreat Dis Int. 2012 Aug 15;11(4):360-71. doi: 10.1016/s1499-3872(12)60193-3. Hepatobiliary Pancreat Dis Int. 2012. PMID: 22893462 Review.
Cited by
-
Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment.Cell Mol Immunol. 2023 Jun;20(6):583-599. doi: 10.1038/s41423-023-00983-5. Epub 2023 Feb 24. Cell Mol Immunol. 2023. PMID: 36823236 Free PMC article. Review.
-
Rat bone marrow mesenchymal stem cells (BMSCs) inhibit liver fibrosis by activating GSK3β and inhibiting the Wnt3a/β-catenin pathway.Infect Agent Cancer. 2022 Apr 19;17(1):17. doi: 10.1186/s13027-022-00432-4. Infect Agent Cancer. 2022. PMID: 35440002 Free PMC article.
-
Multiple Dimensions of using Mesenchymal Stem Cells for Treating Liver Diseases: From Bench to Beside.Stem Cell Rev Rep. 2023 Oct;19(7):2192-2224. doi: 10.1007/s12015-023-10583-5. Epub 2023 Jul 27. Stem Cell Rev Rep. 2023. PMID: 37498509 Review.
-
Novel alternative transplantation therapy for orthotopic liver transplantation in liver failure: A systematic review.World J Transplant. 2020 Mar 31;10(3):64-78. doi: 10.5500/wjt.v10.i3.64. World J Transplant. 2020. PMID: 32257850 Free PMC article.
-
Local but not systemic administration of mesenchymal stromal cells ameliorates fibrogenesis in regenerating livers.J Cell Mol Med. 2019 Sep;23(9):6238-6250. doi: 10.1111/jcmm.14508. Epub 2019 Jun 27. J Cell Mol Med. 2019. PMID: 31245923 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical